New agents in metastatic prostate cancer

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 379-380

  Fizazi, Karim ^a   Massard, Christophe ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CYTOCHROME P450 17; DASATINIB; DENOSUMAB; DOCETAXEL; ENDOTHELIN A RECEPTOR; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; MDV 3100; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; RADIOPHARMACEUTICAL AGENT; SAMARIUM; UNCLASSIFIED DRUG; VASCULOTROPIN; ZOLEDRONIC ACID;

ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVATION; CELL GROWTH; CELL SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; METASTASIS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; RISK REDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL;

ANDROGEN ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CASTRATION; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL;

EID: 70349140015     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70056-5     Document Type: Article

References (15)

1. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
2. Saad F., Gleason D.M., Murray R., et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
3. Fizazi K., Le Maitre A., Hudes G., et al. On behalf of the Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8 (2007) 994-1000
4. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571
5. Ang J.E., Olmos D., and de Bono J.S. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 100 (2009) 671-675
6. Tran C., Ouk S., Clegg N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 (2009) 787-790
7. Scher H.I., Beer T.M., Higano C.S., et al. Phase I/II study of MDV3100 in patients with progressive castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol 2 (2008) abstr 5006.
8. Guise T.A. Molecular mechanisms of osteolytic bone metastases. Cancer 88 12 Suppl (2000) 2892-2898
9. Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27 (2009) 1564-1571
10. James N.D., Caty A., Borre M., et al. Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, Phase II trial. Eur Urol 55 (2009) 1112-1123
11. Fizazi K., Beuzeboc P., Lumbroso J., et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009 Apr 13) [Epub ahead of print].
12. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8 (2008) 497-511
13. Olmos D., Arkenau H.T., Ang J.E., et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 20 (2009) 27-33
14. Attard G., Swennenhuis J.F., Olmos D., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69 (2009) 2912-2918
15. Massard C., Chauchereau A., and Fizazi K. The quest for the 'bony Grail' of detecting circulating tumour cells in patients with prostate cancer. Ann Oncol 20 (2009) 197-199